Healthy Skepticism Library
Items published during the years 2000 to 2009
There are 14385 items in the Healthy Skepticism Library that were published during the years 2000 to 2009.
Page 128 of 144 pages ‹ First < 126 127 128 129 130 > Last ›
HSL3809
Moynihan R.
The making of a disease: female sexual dysfunction.
BMJ 2003 Jan 4; 326:(7379):45-7
http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=12511464
HSL18277
Ford N, 't Hoen E, McKee M
Trade concerns must not be allowed to set the public health agenda
Lancet 2003 Jan 4; 361:(9351):71 - 72
http://www.lancet.com/journals/lancet/article/PIIS0140-6736(03)12123-X/fulltext?version=printerFriendly
HSL18278
Sweet M
Lessons from the HRT story
BMJ 2003 Jan 4; 326:(7379):58
http://www.bmj.com/cgi/content/full/326/7379/58
HSL996
Kirkey S.
Relief from hot flashes can come from anti-depressants
CanWest News Service 2003 Jan 3
HSL997
California Group Claims Pharmacia Illegally Promoted Pain Treatment Bextra for Off-Label Uses
The California Healthline 2003 Jan 3
HSL998
Bush Administration's Proposed Physician Gift Guidelines Criticized by Pharmaceutical Industry
California Healthline 2003 Jan 3
HSL999
Mokhiber R.
The 10 Worst Corporations of 2002
Focus on the Corporation 2003 Jan 3
http://www.multinationalmonitor.org/mm2002/02december/dec02corp1.html
HSL1187
Marcus , Erin N.
When TV commercials play the doctor
The New York Times 2003 Jan 3
http://www.nytimes.com/2003/01/03/opinion/03MARC.html
HSL1195
Kristiansen IS.
Broadening the concept of competing interests
BMJ 2003 Jan 3; 325:(7377):1375
http://bmj.com/cgi/eletters/325/7377/1375
HSL3681
Meek C.
Direct-to-consumer advertising (DTCA) of Prescription Medicines: Fourth Quarterly UpdatedOctober to December 2002.
London: Royal Pharmaceutical Society of Great Britain 2003 Jan 3
http://www.rpsgb.org/pdfs/dtcarev0212.pdf
HSL1612
Wood W, Quinn JM.
Forewarned and forearmed? Two meta-analytic syntheses of forewarnings of influence appeals
Psychol Bull 2003 Jan; 129:(1):119-138
http://content.apa.org/journals/bul/129/1/119
HSL4530
Cassels A.
February is Heart Month.
Common Ground (Vancouver) 2003 Jan 1
http://www.commonground.ca/iss/0602175/cg175_cassels.shtml
HSL5414
Helgason T, Tomasson K, Zoega T.
[Prevalence and distribution of antidepressant, anxiolytic and hypnotic use in 2001].
Laeknabladid 2003 Jan 01; 89:(1):15-22
HSL7655
Roth JM.
Direct-to-consumer advertising of controlled substances.
Am J Health Syst Pharm 2003 Jan 1; 60:(1):91-2
http://www.ajhp.org/cgi/pmidlookup?view=reprint&pmid=12533985
HSL17419
Goldberg M, Davenport B, Mortellito T
When Will the Bubble Burst?: Despite a struggling economy, Pharma companies continue to raise the rewards for sales reps and product managers.
Pharmaceutical Executive 2003 Jan 1
HSL1181
Stokamer CL.
Pharmaceutical gift giving: analysis of an ethical dilemma.
J Nurs Adm 2003 Jan; 33:(1):48-51
HSL1212
Gahart MT, Duhamel LM, Dievler A, Price R.
Examining the FDA's oversight of direct-to-consumer advertising.
Health Aff (Millwood) 2003 Jan-Jun; Suppl:
http://content.healthaffairs.org/cgi/reprint/hlthaff.w3.120v1
HSL1218
Evans GR, Packham DE.
Ethical issues at the university-industry interface: a way forward?
Sci Eng Ethics 2003 Jan; 9:(1):3-16
HSL1220
Dubois RW.
Pharmaceutical promotion: don't throw the baby out with the bathwater.
Health Aff (Millwood) 2003 Jan-Jun; Suppl:
http://content.healthaffairs.org/cgi/reprint/hlthaff.w3.96v1
HSL1235
Calfee JE.
What do we know about direct-to-consumer advertising of prescription drugs?
Health Aff (Millwood) 2003 Jan-Jun; Suppl:
http://content.healthaffairs.org/cgi/reprint/hlthaff.w3.116v1
HSL1241
Bodenheimer T.
Two advertisements for TV drug ads.
Health Aff (Millwood) 2003 Jan-Jun; Suppl:
http://content.healthaffairs.org/cgi/reprint/hlthaff.w3.112v1
HSL1242
Bircher AJ, Surber C.
Unregulated alternative medicine.
J Drugs Dermatol 2003 Jan; 2:(1):58-61
HSL1245
Batchlor E, Laouri M.
Pharmaceutical promotion, advertising, and consumers.
Health Aff (Millwood) 2003 Jan-Jun; Suppl:
http://content.healthaffairs.org/cgi/reprint/hlthaff.w3.109v1
HSL1249
Avorn J.
Advertising and prescription drugs: promotion, education, and the public's health.
Health Aff (Millwood) 2003 Jan-Jun; Suppl:
http://content.healthaffairs.org/cgi/reprint/hlthaff.w3.104v1
HSL1800
Weissman JS, Blumenthal D, Silk AJ, Zapert K, Newman M, Leitman R.
Consumers' reports on the health effects of direct-to-consumer drug advertising.
Health Aff (Millwood) 2003 Jan-Jun; Suppl:
http://content.healthaffairs.org/cgi/reprint/hlthaff.w3.82v1
HSL1801
Weatherall D.
Problems for biomedical research at the academia-industrial interface.
Sci Eng Ethics 2003 Jan; 9:(1):43-8
HSL1803
Vogel RJ, Ramachandran S, Zachry WM.
A 3-stage model for assessing the probable economic effects of direct-to-consumer advertising of pharmaceuticals.
Clin Ther 2003 Jan; 25:(1):309-29
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VRS-4833JPP-S&_coverDate=01%2F31%2F2003&_alid=295787923&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=6242&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=dba690738e220c9c57bacf614e822901
HSL4720
Mamdani B.
He's ethical but has bad taste...
Issues Med Ethics 2003 Jan-Mar; 11:(1):24
HSL7650
Bjerrum L, Foged A.
Patient information leaflets--helpful guidance or a source of confusion?
Pharmacoepidemiol Drug Saf 2003 Jan-Feb; 12:(1):55-9
HSL9939
Wiggins WP.
Pfizer-Pharmacia: the smart fit for the future.
Expert Opin Investig Drugs 2003 Jan; 12:(1):1-3
http://www.expertopin.com/doi/abs/10.1517/13543784.12.1.1
HSL10634
Boos J.
Off label use--label off use?
Ann Oncol 2003 Jan; 14:(1):1-5
http://annonc.oxfordjournals.org/cgi/content/full/14/1/1
HSL10641
Thomas N, Fifer SK.
The combination of collaborative drug therapy management and E-prescribing.
Manag Care Interface 2003 Jan; 16:(1):38-42,
HSL10649
Cimons M.
Drug costs threaten patent protection.
Nat Med 2003 Jan; 9:(1):9
http://www.nature.com/doifinder/10.1038/nm0103-9b
HSL10653
Singer RS, Finch R, Wegener HC, Bywater R, Walters J, Lipsitch M.
Antibiotic resistance--the interplay between antibiotic use in animals and human beings.
Lancet Infect Dis 2003 Jan; 3:(1):47-51
http://linkinghub.elsevier.com/retrieve/pii/S1473309903004900
HSL16746
Wolfe SM.
Remedies needed to address the pathology in reporting adverse reactions and Food and Drug Administration use of reports.
J Gen Intern Med 2003 Jan; 18:(1):72-3
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1494800/?tool=pubmed
HSL192
Katz D, Caplan AL, Merz JF.
All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift-giving.
Am J Bioeth 2003; 3:(3):39-46
http://www.ingentaconnect.com/content/routledg/ajob/2003/00000003/00000003/art00027
HSL1174
Williams-Jones B, Corrigan OP.
Rhetoric and hype: where's the 'ethics' in pharmacogenomics?
Am J Pharmacogenomics 2003; 3:(6):375-83
HSL1175
Wager E, Field EA, Grossman L.
Good publication practice for pharmaceutical companies.
Curr Med Res Opin 2003; 19:(3):149-54
HSL1180
Tsai AC.
Conflicts between commercial and scientific interests in pharmaceutical advertising for medical journals.
Int J Health Serv 2003; 33:(4):751-68
HSL1190
Manima A.
Ethical issues in palliative care: considerations.
J Pain Palliat Care Pharmacother 2003; 17:(3-4):141-9;
HSL1205
Hill S, Freemantle N.
A role for two-stage pharmacoeconomic appraisal? Is there a role for interim approval of a drug for reimbursement based on modelling studies with subsequent full approval using phase III data
Pharmacoeconomics. 2003; 21:(11):761-7
HSL1216
Fisher MA.
Physicians and the pharmaceutical industry: a dysfunctional relationship.
Perspect Biol Med 2003 Spr; 46:(2):254-72
http://www.ncbi.nlm.nih.gov/pubmed/12721524
HSL1224
Desmet C.
Pharmaceutical firms' generosity and physicians: legal aspects in Belgium.
Med Law 2003; 22:(3):473-87
http;//www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14626881
HSL1226
de Lissovoy G.
Weighing the evidence: trends in managed care formulary decision making.
J Clin Psychiatry 2003; 64:
http://www.unboundmedicine.com/evidence/ub/citation/14680425/Weighing_the_evidence:_trends_in_managed_care_formulary_decision_making_
HSL1234
Carter T.
Pfizer and its competitive marketing challenges.
J Hosp Mark Public Relations 2003; 14:(2):85-97
HSL1237
Bozik M.
He who pays the piper calls the tune: the role of the industry sponsor in acute stroke trials.
Eur Neurol 2003; 49:(2):128-30
http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=ENE49128
HSL1239
Bonnemain B.
[When blood and meat were drugs]
Rev Hist Pharm (Paris).2003;51(340):611-24 2003; 51:(340):611-24
HSL1240
Bond C, Hannaford P.
Issues related to monitoring the safety of over-the-counter (OTC) medicines.
Drug Saf 2003; 26:(15):1065-74
HSL1246
Baker E, Newnes C, Myatt H.
Drug companies and clinical psychology.
Ethical Hum Sci Serv 2003 Fal; 5:(3):247-53
HSL1400
Hargreaves I.
Towards a better map: Science, the public and the media
Economic and Social Research Council (ESRC), 2003
http://web.archive.org/web/20040804071704/http://www.esrc.ac.uk/esrccontent/downloaddocs/Mapdocfinal.pdf
HSL1820
Chen P; Paul, Weiss, Rifkind, Wharton & Garrison LLP, New York, NY, USA.
Education or promotion?: Industry-sponsored continuing medical education (CME) as a center for the core/commercial speech debate
Food Drug Law J. 2003; 58:(3):473-509
HSL1900
Shah S.
Globalization of clinical research by the pharmaceutical industry.
Int J Health Serv 2003; 33:(1):29-36
HSL1904
Radinsky G.
The spotlight on PBMs: federal enforcement of the anti-kickback statute on the pharmaceutical benefit management industry.
J Health Law 2003 Spr; 36:(2):213-46
HSL1905
Potts M.
Two pills, two paths: a tale of gender bias.
Endeavour 2003; 27:(3):127-30
HSL1910
Motchane JL.
Health for all or riches for some: WHO's responsible?
Int J Health Serv 2003; 33:(2):395-400
HSL2044
Kay J.
The Truth about Markets: Why Some Nations are Rich but Most Remain Poor
London: Penguin Books 2003
http://www.penguin.co.uk/nf/Book/BookDisplay/0,,0_0140296727,00.html
HSL2235
Malugani M.
Want a Future in Pharmaceutical Sales?
2003
http://healthcare.monster.com/pharm/articles/pharmsales/
HSL2281
Hubbard R, Bayarri MJ.
Confusion over measures of evidence versus errors in classical statistical testing.
Am Statistician 2003; 57:171-182
HSL3692
Health Canada.
Health Protection Legislation. Detailed Legislative Proposal.
Ottawa: Health Canada. 2003
http://www2.itssti.hc-sc.gc.ca/HPCB/Policy/LegislativeRenewal.nsf/fb7c4e1fc0e11e1c85256d24006a12e5/b89331835ada362b85256d3d004f10f3/$FILE/WEBSITEENGLPROPOSALFINAL.pdf
HSL3808
Cohen D, Hoeller K.
Screening for depression: preventive medicine or telemarketing?
Ethical Hum Sci Serv 2003 Spr; 5:(1):3-6
HSL4809
Carr DM.
Pfizer's epidemic: a need for international regulation of human experimentation in developing countries.
Case West Reserve J Int Law 2003 Win; 35:(1):15-53
HSL4907
McCabe AR.
A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
Suffolk Univ Law Rev 2003; 36:(3):787-819
HSL5100
Breslow LH.
The Best Pharmaceuticals for Children Act of 2002: the rise of the voluntary incentive structure and congressional refusal to require pediatric testing.
Harvard J Legis 2003 Win; 40:(1):133-93
HSL5292
Rossman G, Rallis S.
Learning in the Field. An Introduction to Qualitative Research. 2nd Edn
Thousand Oaks: Sage Publications 2003
HSL5429
Gilovich T, Griffin D, Kahneman D.
Heuristics and biases: The psychology of intuitive judgment
Cambridge: Cambridge University Press 2003
HSL5591
Russell FM, Shann F, Curtis N, Mulholland K.
Evidence on the use of paracetamol in febrile children.
Bull World Health Organ 2003; 81:(5):367-72
http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0042-96862003000500011&lng=en&nrm=iso&tlng=en
HSL19335
Stell LK.
Physicians' conflicts of interest.
APA Newsl Philos Med 2003; 3:(1):161-4
http://www.ncbi.nlm.nih.gov/pubmed/15115011
HSL7042
Eaton T. Fores Research Center
There Are No 'Chemical Imbalances'
2003
http://www.etfrc.com/ChemicalImbalances.htm
HSL7329
Pastakia S, Wertheimer AI.
Direct to consumer advertising of prescription vs. non-prescription drugs in the United States
Journal of Social and Administrative Pharmacy 2003; 20:(6):197-203
HSL7331
Direct-to-consumer advertising and patients
WHO Drug Information 2003; 17:(4):262-3
HSL7334
Gillat A.
Compulsory licensing to regulated licensing: effects on the conflict between innovation and access in the pharmaceutical industry.
Food Drug Law J 2003; 58:(4):711-40
HSL7335
Shaeffer J.
Prescription drug advertising--should states regulate what is false and misleading?
Food Drug Law J 2003; 58:(4):629-48
HSL7340
Levy S.
Will yuletide sales be torrid or tepid?
Drug Topics 2003; 147:(23):86-89
HSL7341
Monaghan MS, Turner PD, Houghton BL, Markert RJ, Rich EC, .
Pharmacotherapy cost comparison among health professional students
American Journal of Pharmaceutical Education 2003; 67:(3):
HSL7342
D'souza AO, Lively BT, Siganga W, Goodman MH.
Effects of direct-to-consumer advertising of prescription drugs: Perceptions of primary care physicians
Journal of Pharmaceutical Marketing and Management 2003; 15:(3):61-75
HSL7343
Shah S, Holmes ER, Desselle SP.
The use of persuasion in print DTC advertisements of prescription drugs: A content analysis of leading consumer magazines from 1995-2000
Journal of Pharmaceutical Marketing and Management 2003; 15:(3):23-43
HSL7344
Young HN.
'Look george, there's another one!' - The volume and characteristics of direct-to-consumer advertising in popular magazines
Journal of Pharmaceutical Marketing and Management 2003; 15:(3):7-21
HSL7345
Patel RA, Ravnan MC.
Consumer-directed advertising of prescription medications
California Journal of Health System Pharmacy 2003; 15:(6):15-18
HSL7346
Sax B.
Generic pain management continues to grow
Pharmacy Times 2003; 69:(11):
HSL7352
Schwartz A.
Why generics will benefit from today's trends
US Pharmacist 2003; 28:(11):3-4, 10-12
HSL7353
Santhouse A, Albano D.
Evaluation of Wyeth medical communications written responses and the impact on prescribing
Drug Information Journal 2003; 37:(4):445-450
HSL7413
Peppin P, Carty E.
Signs of inequality: constructing disability in antidepressant drug advertising.
Health Law Journal 2003; 11:(Special Ed):161-84
http://web.archive.org/web/20061010052207/http://www.law.ualberta.ca/centres/hli/pdfs/hlj/2003_Special/10_Peppin%20&%20Carty.pdf
HSL7448
Morin K, Morse LJ.
The ethics of pharmaceutical industry gift-giving: the role of a professional association.
Am J Bioeth 2003 Sum; 3:(3):54-5
http://www.ncbi.nlm.nih.gov/pubmed/14594494
HSL7538
Kaitin KI, Cairns C.
The new drug approvals of 1999, 2000, and 2001: Drug development trends a decade after passage of the Prescription Drug User Fee Act of 1992
Drug Information Journal 2003; 34:(7):357-371
HSL7540
Congress debates PBMs and medicare while FDA considers changes to DTC regulation
Formulary 2003; 38:(11):657-658
HSL7541
Chi J.
Discount cards are serving as safety net to many seniors
Drug Topics 2003; 147:(18):62
HSL7543
Kayne S.
New weapons in the fight against depression and breast cancer
New Zealand Pharmacy 2003; 23:(11):21
HSL7544
Holmes ER, Desselle SP.
The prevalence of informational appeals in direct-to-consumer advertisements of prescription drugs among leading consumer magazines
Journal of Social and Administrative Pharmacy 2003; 20:(4):132-141
HSL7547
Thompson A.
Patent expiries - How should they affect prescribing advice?
Pharmaceutical Journal 2003; 271:(7272):587-589
HSL7548
McNaughton EL, Goodridge CM.
The Canadian approach to freedom of expression and the regulation of food and drug advertising.
Food Drug Law J 2003; 58:(3):521-36
HSL7549
Blackwell AE, Beck JM
Drug manufacturers' First Amendment right to advertise and promote their products for off-label use: Avoiding a pyrrhic victory
Food and Drug Law Journal 2003; 58:(3):439-462
HSL7550
Evans GW, Friede AI
The Food and Drug Administration's regulation of prescription drug manufacturer speech: a First Amendment analysis.
Food Drug Law J. 2003; 58:(3):365-437
HSL7552
Kahan JS, Shapiro JK.
The First Amendment and the Food and Drug Administration's regulation of labeling and advertising: three proposed reforms.
Food Drug Law J 2003; 58:(3):353-64
HSL7554
Gilhooley M.
The Supreme Court checks out drug promotion restrictions.
Food Drug Law J 2003; 58:(3):347-52
HSL7555
Gibbs JN, Ferrari PL, Murphy AM;
Ripe for revision: Reassessing the constitutionality of Food and Drug Administration restrictions on protected speech
Food and Drug Law Journal 2003; 58:(3):331-345
HSL7557
Waxman HA.
A history of adverse drug experiences: Congress had ample evidence to support restrictions on the promotion of prescription drugs.
Food Drug Law J 2003; 58:(3):299-312
HSL7558
Wechsler J.
Regulators and legislators address pharmaceutical rules and coverage - FDA offers new policies to relate enforcement to product risk
Formulary 2003; 38:(10):606-7
HSL7564
Weems LK.
Importation and re-importation of prescription drugs: So what can we do about it?
Florida Pharmacy Today 2003; 68:(9):18
HSL7566
Casteuble T.
HDMA Foundation report surveys industry's barcode readiness
HealthCare Distributor 2003; 55:(4):15,17
HSL7606
Field RI.
Maine's plan to lower drug costs for the uninsured passes a major legal test
P and T 2003; 28:(9):593
Page 128 of 144 pages ‹ First < 126 127 128 129 130 > Last ›
